144750-82-3

Usage

Uses

Used in Pharmaceutical Industry:
1H-Pyrazolo[3,4-d]pyrimidine-4,6-diamine, 3-bromois used as a key intermediate in the synthesis of various pharmaceutical compounds for its potent antiproliferative and anti-inflammatory properties. Its ability to inhibit the proliferation of cancer cells and reduce inflammation makes it a promising candidate for the development of novel therapeutic agents.
Used in Cancer Treatment:
1H-Pyrazolo[3,4-d]pyrimidine-4,6-diamine, 3-bromois used as an anticancer agent for its potential to target and inhibit the growth of cancer cells. Its antiproliferative activity allows it to disrupt the cell cycle and induce apoptosis in cancer cells, making it a valuable tool in the fight against various types of cancer.
Used in Autoimmune Disease Treatment:
1H-Pyrazolo[3,4-d]pyrimidine-4,6-diamine, 3-bromois used as a potential therapeutic agent for the treatment of autoimmune diseases due to its anti-inflammatory properties. Its ability to modulate the immune system and reduce inflammation can help alleviate the symptoms and progression of autoimmune disorders.
Used in Drug Development Research:
1H-Pyrazolo[3,4-d]pyrimidine-4,6-diamine, 3-bromois used as a valuable research tool for the development of novel therapies for various diseases. Its unique structure and pharmacological properties provide insights into the design and synthesis of new drugs with improved efficacy and reduced side effects.

Upstream product

• 5413-80-9 2,4-Diamino-7H-pyrazolo<3,4-d>pyrimidine 
• 96575-35-8 2-Amino-5-bromo-4(3H)-oxo-7H-pyrazolo<3,4-d>pyrimidine 

Downstream Products

• 908143-21-5 N-[1-[5-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-3-(tert-butyl-dimethyl-silanyloxy)-4-hydroxy-tetrahydro-furan-2-yl]-3-bromo-4-(dibutylamino-methyleneamino)-1H-pyrazolo[3,4-d]pyrimidin-6-yl]-formamide 
• 908143-20-4 N-[1-{5-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-3,4-dihydroxy-tetrahydro-furan-2-yl}-3-bromo-4-(dibutylamino-methyleneamino)-1H-pyrazolo[3,4-d]pyrimidin-6-yl]-formamide 
• 908143-17-9 3-bromo-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine 
• 144750-86-7 Dimethyl N-<4-<2-(2,4-diaminopyrazolo<3,4-d>pyrimidin-5-yl)ethynyl>benzoyl>-L-glutamate 

Relevant academic research and scientific papers

Pyrazolo[3,4-d]pyrimidine ribonucleosides related to 2-aminoadenosine and isoguanosine: Synthesis, deamination and tautomerism

The syntheses and properties of 8-aza-7-deazapurine (pyrazolo[3,4-d] pyrimidine) ribonucleosides related to 2-aminoadenosine and isoguanosine are described. Glycosylation of 8-aza-7-deazapurine-2,6-diamine 5 with 1-O-acetyl-2,3,5-tri-O-benzoyl-β-d-ribofur

PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS

New pyrrolotriazinone derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositide 3-Kinases (PI3Ks).

Real-time linear detection probes: sensitive 5'-minor groove binder-containing probes for PCR analysis

Oligonucleotide probes/conjugates are provided along with method for their use in assays to monitor amplification wherein the signal produced does not rely on 5′ nuclease digestion.

Synthesis of pyrazolo 3,4-d pyrimidine analogues of the potent agent N-4-2-2-amino-4 3H-oxo-7H-pyrrolo 2,3-d pyrimidin-5-yl ethylbenzoyl-L-glutamic acid (LY231514)

Several pyrazolo[3,4-d]pyrimidine analogues of the potent antitumor agent N-{4-[2-(2-amino-4(3 H)-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid (LY231514, 5) have been prepared. A principal synthetic step proved to be a palladium-cata